Shortening the Timeline from Customer into Clinics: Development of a Downstream Processing Platform for Adeno-associated virus (AAV)
Inefficient manufacturing processes and small patient populations result in high manufacturing costs. An economical and scalable method for AAV purification can help to reduce these costs. Learn more about IDT Biologika´s platform technology for the purification of AAV particles.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
